Skip to main content

Publications

Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint InhibitorsThis study explored whether inherited genetic factors influence the risk of immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICIs). Researchers analyzed genomic data from 117 patients with metastatic cancers enrolled in the Personalized OncoGenomics (POG) program and reviewed their treatment-related toxicities. They found that patients carrying HLA-B27 family alleles were significantly more likely to develop severe hepatitis or pneumonitis when treated with certain ICI combinations. The findings suggest that germline genetic variation may help identify patients at increased risk of serious immunotherapy-related side effects and support more personalized treatment planning.
Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy durationThis study investigated whether genomic markers of homologous recombination deficiency (HRD) can predict response to platinum-based chemotherapy in advanced gastrointestinal (GI) and thoracic cancers. Using whole genome and transcriptome sequencing data from 223 patients, researchers found that the SBS3 mutational signature was associated with longer time to progression on platinum therapy in GI cancers, while HRD scores alone were not. The analysis also identified additional HR-related gene alterations beyond BRCA1/2 that may contribute to treatment sensitivity. These findings suggest that SBS3 may help identify patients most likely to benefit from platinum-based therapies.
The impact of whole genome and transcriptome analysis (WGTA) on predictive biomarker discovery and diagnostic accuracy of advanced malignanciesThis study evaluated the clinical utility of whole genome and transcriptome analysis (WGTA) in 652 patients with advanced cancers. WGTA identified actionable genomic alterations linked to approved targeted therapies in 6% of cases at the time of testing, increasing to 16% when assessed using updated 2021 treatment guidelines. Genomic analysis also supported accurate tumor classification, confirming most histopathologic diagnoses and successfully assigning a specific tumor type to all malignancies of uncertain histogenesis. The findings demonstrate WGTA’s value for molecular profiling and tumor diagnosis, supporting its growing role in precision oncology.
TMBur: a distributable tumor mutation burden approach for whole genome sequencingThis study developed TMBur, a standardized and shareable workflow for measuring tumor mutation burden (TMB) from whole genome sequencing data. TMBur produced identical TMB estimates across multiple research centres, addressing variability caused by different analytical methods. In a cohort of 90 patients with advanced cancer treated with immune checkpoint inhibitors, a TMB of ≥10 mutations/Mb was associated with significantly longer time to disease progression. These findings demonstrate that TMBur provides reproducible and clinically meaningful TMB estimates, supporting equitable patient selection for immunotherapy and clinical trials across jurisdictions.
Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysisThis case report describes an exceptional response to immune checkpoint inhibitor therapy in a patient with metastatic uveal melanoma, a cancer type that typically has poor outcomes and low response rates to immunotherapy. After treatment with ipilimumab/nivolumab followed by nivolumab maintenance, the patient showed near-complete resolution of metastatic disease, with only partial regression of a liver lesion. Whole genome and transcriptome analysis of the residual tumor revealed alterations in genes involved in T-cell immune responses and a high level of plasma cell infiltration, which may relate to disease control. Germline variants and clinical features such as elevated BMI and treatment-induced vitiligo were also noted as potential contributors to response. The findings suggest immune microenvironment features, particularly plasma cells, may influence immunotherapy success in uveal melanoma.
Whole-genome and transcriptome analysis enhances precision cancer treatment optionsThis study evaluated the clinical impact of integrating whole-genome and transcriptome analysis (WGTA) in 570 patients with advanced or metastatic cancers enrolled in the Personalized OncoGenomics program. Using combined DNA and RNA profiling, a multidisciplinary tumour board identified clinically actionable targets in 83% of patients, with 37% receiving WGTA-informed therapies. Notably, RNA expression data contributed to two-thirds of treatment decisions and alone guided 25% of therapies. Among 248 WGTA-informed treatments, 46% led to clinical benefit. The findings demonstrate that integrating transcriptomic with genomic data significantly expands treatment options and improves alignment to effective precision cancer therapies.
Whole-genome and transcriptome analysis of advanced adrenocortical cancer highlights multiple alterations affecting epigenome and DNA repair pathwaysThis study used whole-genome and transcriptome sequencing to characterize metastatic adrenocortical cancer (ACC) in seven patients, a rare malignancy with limited treatment options. Integrative genomic analysis identified frequent mutations in TP53 and CTNNB1, along with widespread loss of heterozygosity and alterations in genes involved in cell cycle regulation, DNA repair, and telomere maintenance. HRDetect analysis indicated that a subset of tumors exhibited homologous recombination deficiency (HRD). Additional findings highlighted disruptions in epigenetic regulators, including SWI/SNF complex genes and histone-modifying enzymes. The results suggest that HRD and epigenomic alterations represent potential therapeutic vulnerabilities in ACC and support further exploration of targeted treatment strategies.
A platform for oncogenomic reporting and interpretationThis study introduces the Platform for Oncogenomic Reporting and Interpretation (PORI), an open-source framework designed to streamline the interpretation and reporting of complex cancer genomic data. PORI integrates automated analysis with a graph-based knowledge base and supports expert manual curation to improve the clinical interpretation of somatic variants. The platform was validated by analyzing nearly 10,000 tumors from The Cancer Genome Atlas, successfully identifying therapeutically relevant genomic alterations and generating comprehensive clinical reports. By reducing the burden of manual variant interpretation, PORI provides a scalable solution to support precision oncology programs and facilitate the broader clinical implementation of comprehensive genomic sequencing.
The Neoantigen Landscape of the Coding and Noncoding Cancer Genome SpaceThis pan-cancer study analyzed whole-genome and transcriptome data from 574 patients with advanced cancers to evaluate whether including noncoding regions improves prediction of immunotherapy response. Researchers compared tumor mutation burden (TMB) and tumor neoantigen count (TNC), including neoantigens derived from both coding and noncoding regions, in a subset of 80 immunotherapy-treated patients. Results showed that TMB remained the strongest predictor of response to immune checkpoint inhibitors, while adding noncoding-derived neoantigens did not improve predictive performance. Although noncoding regions contribute additional potential neoantigens, the study concludes they do not enhance current clinical prediction of immunotherapy benefit.
Early-stage economic analysis of research-based comprehensive genomic sequencing for advanced cancer careThis study evaluated the early clinical and economic impact of whole genome and transcriptome analysis (WGTA) within the Personalized OncoGenomics (POG) program using real-world data and matched usual-care controls. A cohort of 230 patients receiving WGTA was compared with 230 matched controls to assess costs, survival, and health system effects over one year. While no overall survival difference was observed between groups, patients who received WGTA-informed therapies experienced a mean survival gain of 2.49 months. WGTA was associated with higher short-term healthcare costs, though sequencing costs declined over time. The findings suggest potential survival benefits in selected patients and improving cost-effectiveness as genomic testing becomes more widely implemented.
NTRK2 Fusion driven pediatric glioblastoma: Identification of oncogenic Drivers via integrative Genome and transcriptome profilingThis brief report describes the first identified case of a NACC2–NTRK2 fusion in a histologically confirmed glioblastoma. Through clinical oncogenomic profiling, the fusion oncogene was detected in a pediatric cerebellar tumor and would not have been identified using routine diagnostic methods. The finding highlights the ability of comprehensive genome sequencing to uncover rare, actionable driver alterations that can directly inform treatment opportunities. Overall, the case underscores the clinical value of advanced genomic profiling in improving molecular diagnosis and expanding therapeutic options in aggressive pediatric brain tumors such as glioblastoma.
Whole-slide laser microdissection for tumour enrichmentThis study describes a semi-automated laser microdissection method that improves the use of formalin-fixed, paraffin-embedded (FFPE) tissue samples for whole genome and transcriptome sequencing in precision oncology. The approach enables efficient separation of tumour and normal cell populations from routine pathology specimens, enriching tumour content by up to 67% while generating DNA and RNA of sufficient quality for comprehensive genomic analysis. By overcoming the challenges of obtaining fresh tumour biopsies, this method supports the broader clinical implementation of genome-scale sequencing and expands access to precision oncology using routinely collected archival tissue samples.
Matching methods in precision oncology: An introduction and illustrative exampleThis study evaluated the effectiveness of the Personalized OncoGenomics (POG) program using quasi-experimental matching methods to compare outcomes between sequenced patients and matched controls. A cohort of 230 patients with advanced cancers who underwent whole genome and transcriptome analysis (WGTA) was matched 1:1 with POG-naive controls using propensity score and genetic matching approaches. Overall survival did not differ significantly between groups. However, patients whose WGTA results directly informed treatment changes showed a significantly reduced risk of death compared to controls. The findings suggest that survival benefit in precision oncology is closely tied to whether genomic results lead to actual treatment modification.
Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In?This study investigated the molecular features that distinguish early-onset pancreatic ductal adenocarcinoma (EOPC) from PDAC occurring at older ages. Using genomic and transcriptomic data from over 500 PDAC samples, researchers compared mutation patterns and gene expression profiles across age groups. EOPC tumors showed distinct patterns of CDKN2A inactivation, with more frequent biallelic loss through homozygous deletion rather than combined mutation and copy loss. Additionally, FOXC2 expression was increased in EOPC and was associated with epithelial-to-mesenchymal transition pathways, including genes involved in tumour invasion and progression. These findings identify unique molecular characteristics of EOPC that may improve understanding of disease biology and guide future therapeutic strategies.
Uncovering Clinically Relevant Gene Fusions with Integrated Genomic and Transcriptomic Profiling of Metastatic CancersThis study evaluated the ability of whole-genome and transcriptome sequencing (WGS and RNA-seq) to detect clinically relevant gene fusions in 570 patients with advanced cancers. Using a consensus fusion-calling pipeline, researchers identified recurrent fusions across both DNA and RNA data, including known drivers such as EML4–ALK and novel fusion partners involving oncogenes like NTRK2 and NTRK3. The combined approach detected a broader and more diverse set of fusions than would be expected using standard commercial gene panels. The findings highlight that integrated WGS and RNA-seq improve fusion discovery and enable retrospective identification of clinically actionable alterations.
Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid TumorsThis study used whole genome and transcriptome analysis (WGTA) to evaluate biomarkers associated with response to immune checkpoint inhibitors (ICIs) in a pan-cancer cohort of 98 patients with metastatic, predominantly pretreated disease. Tumor mutation burden was found to be the strongest predictor of time to progression, while immune microenvironment features such as CD8+ T-cell activity and macrophage polarization ratios were more strongly associated with overall survival. PD-L1 expression did not correlate with clinical benefit. The results suggest that combining genomic and immune-related WGTA biomarkers improves patient stratification for immunotherapy response compared to single markers alone.
Evaluating genomic biomarkers associated with resistance or sensitivity to chemotherapy in patients with advanced breast and colorectal cancerThis retrospective multi-centre study used data from the Personalized OncoGenomics (POG) program to evaluate whether transcriptomic biomarkers predict chemotherapy response in advanced breast and colorectal cancer. Patients treated with common agents such as capecitabine, paclitaxel, irinotecan, oxaliplatin, and bevacizumab were analyzed, with expression levels of selected genes measured from whole tumour RNA sequencing. The study found a modest association between higher TYMP expression and capecitabine sensitivity in breast cancer, and between higher DICER1 expression and response to bevacizumab-based therapy in colorectal cancer. Overall, the findings suggest that mRNA expression biomarkers may help refine predictions of chemotherapy response, but require further validation.
Rearrangement-mediated cis-regulatory alterations in advanced patient tumors reveal interactions with therapyThis study investigated how somatic structural variants (SVs) influence gene regulation in 570 recurrent and metastatic cancers using integrated whole genome and RNA sequencing. The researchers found that SVs frequently altered the expression of nearby genes, including oncogenes and other cancer-related genes, with many of these changes associated with poorer patient survival. Prior cancer treatments, such as DNA alkylating agents, taxanes, anthracyclines, and topoisomerase I inhibitors, were linked to distinct patterns of SVs and gene expression changes, suggesting that therapy can reshape the tumour genome. These findings demonstrate that structural variants are important drivers of gene dysregulation in advanced cancers and highlight the value of considering treatment history when interpreting cancer genomes.
A Scalable Strand-Specific Protocol Enabling Full-Length Total RNA Sequencing From Single CellsThis study presents a novel single-cell RNA sequencing (scRNA-seq) protocol that enables high-throughput, full-length sequencing of total RNA from individual cells. Unlike many existing methods that are limited to sequencing only the 3′ or 5′ ends of polyadenylated transcripts, this approach captures both polyadenylated and non-polyadenylated RNAs while preserving strand-specific information. The resulting data provide comprehensive transcript coverage, allowing improved characterization of gene expression and accurate identification of distinct cell types within heterogeneous samples. This method expands the capabilities of single-cell transcriptomics and offers a powerful tool for studying complex tissues, including the diverse cellular environments found in cancer.
Clinical and cost outcomes following genomics-informed treatment for advanced cancersThis study used a quasi-experimental difference-in-difference (DID) approach to evaluate the impact of genomics-informed therapy versus standard care in 346 patients with advanced cancers enrolled in the BC Cancer Personalized OncoGenomics program. Of these, 40% received genomics-guided treatment after sequencing. Analyses showed no major baseline differences between groups. Genomics-informed therapy was associated with a significant increase in time to treatment discontinuation (102 days) and a non-significant trend toward longer time to next treatment. However, it also resulted in substantially higher healthcare costs. The findings suggest genomics-guided treatment may improve treatment durability, particularly in gastrointestinal cancers, but at increased financial cost.
Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinomaThis study evaluated whether routine histological features could predict molecular subtype and prognosis in pancreatic ductal adenocarcinoma (PDAC). By comparing tissue morphology with whole transcriptome sequencing data from the Personalized OncoGenomics (POG) program, the researchers found that tumors with low gland formation and low neutrophil infiltration were strongly associated with the aggressive basal-like/squamous molecular subtype and shorter overall survival. These findings were validated in an independent TCGA cohort and across both primary and metastatic tumors. The study demonstrates that simple pathological features may serve as practical surrogate markers for molecular classification, providing prognostic information when genomic testing is unavailable.
Improved structural variant interpretation for hereditary cancer susceptibility using long-read sequencingThis study assessed the value of long-read sequencing for improving detection and interpretation of germline structural variants (SVs) associated with hereditary cancer risk. In a cohort of 669 advanced cancer patients initially screened using short-read genome sequencing, candidate SVs were further analyzed using Oxford Nanopore long-read sequencing. The approach confirmed several pathogenic variants, clarified the clinical significance of previously ambiguous rearrangements, and reclassified likely benign artifacts. It also resolved complex pathogenic rearrangements affecting genes such as TSC2. The findings demonstrate that long-read sequencing enhances SV validation and interpretation, improving accuracy in hereditary cancer risk assessment and downstream clinical decision-making.
Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer TypesThis study explored the relationship between endogenous retrovirus (ERV) expression, immune activation, and tumour immunogenicity across metastatic cancers. Using integrated genomic, transcriptomic, and clinical data from 199 patients with breast, colorectal, and pancreatic ductal adenocarcinomas, researchers identified a subgroup of “viral mimicry” tumours characterized by increased ERV expression and activation of antiviral immune response pathways. These tumours also showed increased expression of the DNA demethylation gene TET2, suggesting a link between epigenetic regulation and immune activation. The findings reveal a shared ERV-associated immunogenic phenotype across multiple cancer types and provide insight into molecular mechanisms that may influence tumour response to immunotherapies.
Establishing a Framework for the Clinical Translation of Germline Findings in Precision OncologyThis perspective discusses the role of germline genetic variation in large-scale cancer genomics, drawing on experience from the Personalized OncoGenomics program. Using paired tumor-normal whole-genome and transcriptome sequencing in advanced cancer patients, the authors highlight how inherited variants can influence not only cancer risk but also tumour biology, immune response, and treatment outcomes. The paper emphasizes the lack of consensus on how to manage and interpret germline findings beyond established cancer predisposition genes. It proposes a multidisciplinary framework for identifying, evaluating, and returning clinically relevant germline variants, supporting more standardized approaches in precision oncology.
Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysisThis retrospective study evaluated whether whole genome and transcriptome analysis (WGTA) improves patient selection for early-phase clinical trials in advanced cancer. Twenty-eight patients undergoing WGTA were enrolled in clinical trials, with 15 matched to treatment based on molecular findings. Of these, some were selected using single-gene DNA alterations supported by RNA data, while others were matched using genome-wide or expression-based signals. WGTA increased treatment matching approximately threefold compared to DNA-only approaches. However, median treatment duration was short, reflecting the experimental nature of therapies. The study suggests WGTA may enhance trial matching but highlights the need for further evidence on clinical benefit.
Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapesThis study describes the POG570 cohort, a large integrated dataset combining whole genome, transcriptome, and clinical data from patients with advanced and metastatic cancers. The analysis examined how prior therapies shape tumour evolution and genomic landscapes. Exposure to DNA-damaging treatments and alterations in DNA repair genes were associated with therapy-induced mutational signatures, including those linked to platinum-based therapies. The study also identified recurrent coding and non-coding alterations in genes involved in resistance and sensitivity pathways. Additionally, tumour mutation burden and immune-related signatures correlated with survival and immunotherapy response, providing a resource for understanding treatment-driven cancer evolution.
Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolutionThis study investigated the molecular diversity of pancreatic adenocarcinoma by analyzing whole genomes and transcriptomes from purified tumour cells from primary and metastatic tumours. Researchers found that pancreatic cancer subtypes exist along a spectrum of gene expression patterns rather than as distinct categories, reflecting mixtures of different tumour cell populations. Integrated genomic analysis revealed that specific copy number changes and ongoing genomic instability contribute to tumour evolution and disease heterogeneity. These findings provide new insight into how pancreatic cancers develop and progress.
Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic DPYD structural variantThis case report describes a patient with metastatic head and neck squamous cell carcinoma (HNSCC) in whom integrated whole genome and transcriptome analysis identified somatic alterations affecting 5-fluorouracil (5-FU) metabolism. A novel somatic structural variant causing partial deletion of DPYD, along with additional alterations in related metabolic genes, suggested increased tumor vulnerability to fluoropyrimidine therapy. No germline DPYD variants associated with toxicity were detected. Based on these findings, the patient received 5-FU and achieved a rapid but temporary clinical response lasting 17 weeks before relapse. The study suggests that somatic DPYD alterations may serve as potential biomarkers of tumor sensitivity to fluoropyrimidine chemotherapy.
Altered Gene Expression along the Glycolysis-Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic CancerThis study analyzed genomic and transcriptomic data from 325 pancreatic ductal adenocarcinoma (PDAC) patients across multiple cohorts to define metabolic subtypes and their prognostic significance. Tumours were classified into four groups based on glycolytic and cholesterol synthesis gene expression: quiescent, glycolytic, cholesterogenic, and mixed. Glycolytic tumours were associated with the poorest survival in both resectable and metastatic disease, while cholesterogenic tumours showed the most favourable outcomes. Metabolic profiles correlated with oncogenic drivers such as KRAS and MYC amplification and differences in mitochondrial gene expression. The findings suggest that metabolic heterogeneity can stratify PDAC prognosis and may guide development of targeted therapeutic strategies.
Base excision repair deficiency signatures implicate germline and somatic MUTYH aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesisThis study investigated the relationship between germline MUTYH mutations and somatic mutational signatures across a large cohort of 731 advanced cancer patients, building on a case of early-onset pancreatic cancer with biallelic MUTYH deficiency. The analysis showed that tumors with complete loss of MUTYH function exhibited characteristic base-excision repair deficiency signatures and associated driver mutations, such as KRAS G12C. In contrast, monoallelic MUTYH variants alone were not sufficient to generate these mutational patterns. Additional cases confirmed that somatic loss of the second allele can produce similar genomic signatures even in non-classical tumor types. The findings clarify that biallelic, but not heterozygous, MUTYH inactivation is required for the associated mutational signature to emerge in cancer.
Clinical outcomes after whole-genome sequencing in patients with metastatic non-small-cell lung cancerThis study evaluated the impact of the Personalized OncoGenomics (POG) program in 29 patients with metastatic non-small-cell lung cancer using integrated whole genome and transcriptome sequencing. Molecular analysis identified potential cancer drivers in 90% of cases and actionable targets in 72%. Thirteen patients received therapies guided by POG findings, and outcomes were assessed using progression-free survival (PFS) ratios compared to prior treatment lines. Among evaluable patients, 30% experienced improved PFS on genomics-informed therapy. Overall, the results suggest that comprehensive genomic profiling can identify actionable alterations in most NSCLC cases, with a subset of patients deriving measurable clinical benefit.
Comparative Tumor RNA Sequencing Analysis for Difficult-to-Treat Pediatric and Young Adult Patients With CancerThis study evaluated the feasibility and clinical utility of incorporating comparative RNA sequencing (RNA-seq) analysis into precision oncology approaches for children and young adults with difficult-to-treat cancers. Tumour RNA-seq data from 144 patients across multiple clinical sites were compared against more than 11,000 publicly available pediatric and young adult cancer profiles to identify overexpressed genes and pathways. RNA-based analysis provided potentially useful clinical or biological insights for 68.8% of samples, compared with 45.9% for DNA mutation analysis alone. The findings demonstrate that transcriptomic profiling can enhance genomic interpretation and support treatment decision-making, particularly for rare, relapsed, or refractory pediatric cancers.
A high-throughput protocol for isolating cell-free circulating tumor DNA from peripheral bloodThis study developed an automated magnetic bead-based method for isolating circulating tumour DNA (ctDNA) directly from peripheral blood without requiring plasma separation by centrifugation. The approach aims to simplify and improve scalability of ctDNA analysis, which can provide a less invasive and dynamic method for monitoring cancer progression and treatment response compared with tissue biopsies. When tested using cancer patient samples, the method produced comparable allelic fractions of somatic single-nucleotide variants to standard plasma-based ctDNA isolation approaches. The findings demonstrate that direct blood-based ctDNA purification may be a practical alternative for future clinical and research applications in liquid biopsy workflows.
Evaluation of protocols for rRNA depletion-based RNA sequencing of nanogram inputs of mammalian total RNANext generation RNA-sequencing (RNA-seq) is a flexible approach that can be applied to a range of applications including global quantification of transcript expression, the characterization of RNA structure such as splicing patterns and profiling of expressed mutations. Many RNA-seq protocols require up to microgram levels of total RNA input amounts to generate high quality data, and thus remain impractical for the limited starting material amounts typically obtained from rare cell populations, such as those from early developmental stages or from laser micro-dissected clinical samples. Here, we present an assessment of the contemporary ribosomal RNA depletion-based protocols, and identify those that are suitable for inputs as low as 1-10 ng of intact total RNA and 100-500 ng of partially degraded RNA from formalin-fixed paraffin-embedded tissues.
Sources of erroneous sequences and artifact chimeric reads in next generation sequencing of genomic DNA from formalin-fixed paraffin-embedded samplesThis study investigated sequencing artifacts that can arise when using formalin-fixed, paraffin-embedded (FFPE) tissue samples for next-generation sequencing. Researchers identified a major class of artifacts, termed strand-split artifact reads (SSARs), which result from damaged DNA fragments aligning incorrectly during analysis. The study established a framework for understanding how these artifacts are generated and demonstrated that S1 nuclease treatment can reduce sequencing errors, biases, and false-positive variant detection. These findings improve the reliability of genomic analyses using archived FFPE samples.
NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal AdenocarcinomaThis study evaluated the clinical significance of NRG1 gene fusions in pancreatic ductal adenocarcinoma using whole genome and transcriptome sequencing in 47 patients. Three KRAS wild-type tumors were identified, all of which harbored NRG1 fusions involving the ERBB3 ligand. Two patients with NRG1 fusion-positive disease were treated with the HER-family inhibitor afatinib and showed rapid and significant clinical responses. These findings suggest that NRG1 fusions represent a distinct, actionable molecular subtype of pancreatic cancer. The study supports the use of comprehensive genomic profiling to identify patients who may benefit from targeted HER-family inhibition therapies such as afatinib.
The pivotal role of sampling recurrent tumors in the precision care of patients with tumors of the central nervous systemThis study reports the application of the Personalized OncoGenomics (POG) program to central nervous system (CNS) tumors, focusing on recurrent brain and spine cancers. Sixteen patients underwent whole genome and transcriptome sequencing of tumor and matched normal tissue, followed by integrative genomic analysis. Across all cases, clinically relevant genomic alterations were identified, including oncogenic fusions, pathway disruptions, and potential therapeutic targets, which also supported diagnostic refinement. The findings demonstrate the feasibility and clinical utility of comprehensive genomic profiling in CNS tumors. The study highlights the importance of multidisciplinary collaboration, including neurosurgical involvement, to enable effective precision oncology in neuro-oncology care.
Therapeutic Implication of Genomic Landscape of Adult Metastatic SarcomaThis study evaluated the utility of integrated whole genome and transcriptome profiling in 43 patients with advanced or metastatic sarcoma, a highly heterogeneous group of rare cancers. Genomic analysis revealed that structural variants and copy number alterations were the most common abnormalities, while point mutations in known drug targets were relatively uncommon. However, combined DNA and RNA profiling identified potential therapeutic targets in most patients, including cases with TSC2 alterations associated with mTOR pathway sensitivity and clinical benefit from everolimus. The study also identified recurrent sarcoma-specific amplifications and evidence of homologous recombination deficiency in some tumors, suggesting sensitivity to DNA-damaging therapies and supporting biomarker-driven treatment approaches.
Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumorThis case study describes the whole genome and transcriptome analysis of a metastatic well-differentiated grade 3 pancreatic neuroendocrine tumor (PanNET). Comprehensive sequencing of liver metastases was used to identify single-nucleotide variants, copy-number changes, and structural rearrangements, with RNA sequencing confirming their functional relevance. The tumor notably harbored a TSC1-disrupting gene fusion and a novel CHD7–BEND2 fusion, while lacking common alterations in ATRX, DAXX, and MEN1 that are typically seen in pancreatic neuroendocrine neoplasms. These findings expand the molecular characterization of high-grade PanNETs and highlight the role of structural variants in their biology and potential therapeutic targeting.
Application of a Neural Network Whole Transcriptome-Based Pan-Cancer Method for Diagnosis of Primary and Metastatic CancersThis cross-sectional diagnostic study evaluated a whole transcriptome-based machine learning method (SCOPE) for improving cancer classification and identifying tumor origin. Using RNA sequencing data from over 10,000 samples across multiple tumor types and normal tissues, the model was trained to distinguish 40 cancer types and 26 normal tissue classes. In testing on primary mesothelioma, treatment-resistant metastatic cancers, and cancers of unknown primary, SCOPE achieved high diagnostic accuracy (up to 99% in mesothelioma and 86% overall). The method successfully identified likely tumor origins in most uncertain cases, demonstrating that transcriptome-wide profiling can serve as a powerful adjunct to conventional pathology in complex cancer diagnoses.
Whole-genome and transcriptome profiling of a metastatic thyroid-like follicular renal cell carcinomaThis case report describes a 27-year-old male with metastatic thyroid-like follicular renal cell carcinoma (TLFRCC), a rare cancer with limited known genomic data. Integrated whole genome and transcriptome sequencing of the metastatic tumour was performed alongside germline analysis, followed by comparison with TCGA datasets to identify aberrant gene expression and potential therapeutic targets. The tumor showed high expression of multiple oncogenic pathways, including PDGFRA, PDGFRB, MYC, AR, and CDK6. Based on these findings, the patient was treated with sunitinib targeting PDGF receptors, achieving stable disease for more than six months before progression and subsequent treatment with nivolumab. The study highlights how comprehensive genomic profiling can guide therapy selection and support diagnosis in rare cancers.
Temporal Dynamics of Genomic Alterations in a BRCA1 Germline–Mutated Pancreatic Cancer With Low Genomic Instability Burden but Exceptional Response to Fluorouracil, Oxaliplatin, Leucovorin, and IrinotecanThis report describes a case of pancreatic ductal adenocarcinoma with a germline BRCA1 mutation in which whole-genome sequencing was used to assess homologous recombination deficiency (HRD) across multiple tumor biopsies taken at different time points and locations. Despite the presence of a BRCA1 mutation and an exceptional clinical response to FOLFIRINOX chemotherapy, the tumor showed relatively low HRD mutational signatures, suggesting genomic stability at the time of sampling. This apparent paradox was resolved by analyzing the temporal dynamics of HRD, indicating that mutational signatures may reflect historical rather than current DNA repair activity. The study highlights the importance of considering timing when interpreting HRD signatures for therapeutic decision-making.
Comparative RNA-Sequencing Analysis Benefits a Pediatric Patient With Relapsed CancerThis case report describes a pediatric sarcoma that underwent integrated whole-genome and RNA sequencing for clinical genomic profiling. Although DNA sequencing did not identify any actionable mutations, RNA expression analysis revealed biologically relevant therapeutic targets that were not apparent from genomic data alone. Incorporating transcriptomic information into the clinical interpretation led to selection of a targeted therapy, which resulted in a significant clinical response. The study highlights the added value of gene expression profiling in pediatric cancer genomics and proposes a framework for integrating RNA-based evidence alongside DNA mutations to improve identification of treatment opportunities in rare childhood tumors.
Personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision-makingThis study used whole genome and transcriptome sequencing to characterize five cases of metastatic adenoid cystic carcinoma (ACC) enrolled in the Personalized OncoGenomics program. The tumors showed low overall mutational burden but recurrent structural alterations, most commonly MYB–NFIB fusions, with one case showing a related MYBL1–NFIB fusion. Additional findings included mutations in genes involved in chromatin regulation and occasional copy number changes such as MYC amplification and CDKN2A loss. Despite the rarity of actionable point mutations, integrative genomic analysis identified potential therapeutic targets in all cases and informed treatment decisions in several patients, demonstrating the clinical utility of comprehensive profiling in rare cancers.
Application of genomics to identify therapeutic targets in recurrent pediatric papillary thyroid carcinomaThis case report describes two children with multiply relapsed papillary thyroid carcinoma (PTC) who underwent whole genome and transcriptome sequencing to identify potential therapeutic targets. In one patient, a TPM3–NTRK1 fusion with high NTRK1 expression was detected, and comparison with reference datasets confirmed it as an expression outlier. Treatment with an oral TRK inhibitor led to resolution of multiple pulmonary metastases without significant toxicity. In the second patient, a RET fusion was identified as a potentially actionable driver. The findings highlight how integrated genomic profiling can uncover targetable alterations in pediatric PTC and enable effective targeted therapy while reducing reliance on repeated radioactive iodine treatment.
Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive casesThis study provides comprehensive molecular characterization of two cases of ERBB2-amplified colorectal cancer (CRC) using whole genome and transcriptome sequencing alongside complementary protein and copy-number assays. Both tumors were KRAS wild-type and exhibited very high ERBB2 copy number amplification, confirmed by FISH, immunohistochemistry, and protein mass spectrometry. Additional analyses identified alterations in pathways including PIK3CA mutation and dysregulated expression of PTEN, MET, and MUC1, which may contribute to resistance to EGFR- and HER2-targeted therapies. The findings highlight the importance of accurately identifying ERBB2 amplification in CRC and suggest potential molecular mechanisms underlying variability in response to targeted treatment.
Whole genome and whole transcriptome genomic profiling of a metastatic eccrine porocarcinomaThis study presents integrated whole genome and transcriptome profiling of a metastatic eccrine porocarcinoma in a 66-year-old patient, a rare malignant sweat gland tumor. Comparative germline and somatic analyses revealed multiple copy number losses affecting tumor suppressor genes including APC, PTEN, CDKN2A, CDKN2B, and CDKN1A, along with a somatic splice-site variant in CDKN2A. Transcriptomic analysis demonstrated abnormal splicing of CDKN2A isoforms and elevated expression of oncogenes such as EGFR and NOTCH1 despite the absence of coding mutations in these genes. Additional alterations implicated dysregulation of the Wnt pathway. Overall, the findings suggest that complex genomic and transcriptomic interactions, particularly involving CDKN2A loss and cell cycle dysregulation, contribute to the pathogenesis of this rare cancer.
Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencingThis study analyzed whole genome and transcriptome data from liver metastases of five patients with pancreatic neuroendocrine tumors (PNETs) enrolled in a clinical trial. The tumors showed substantial genomic heterogeneity, with most cases exhibiting biallelic loss of MEN1 and DAXX alongside recurrent loss of heterozygosity. One case demonstrated focal MYCN amplification with concurrent APC and TP53 loss, accompanied by a corresponding MYCN-driven transcriptional signature. Another case revealed a germline NTHL1 fusion associated with a distinctive mutational signature. Overall, the findings highlight diverse molecular drivers of PNET progression and suggest that integrated genomic profiling may help explain disease variability and guide treatment selection.
The cost and cost trajectory of whole-genome analysis guiding treatment of patients with advanced cancersThis study estimated the real-world costs of implementing whole-genome analysis (WGA) within the Personalized OncoGenomics (POG) program in British Columbia for patients with advanced cancers. Using data from 2012–2015, the mean cost per patient was approximately CDN$34,886, with sequencing costs decreasing over time but other implementation costs increasing. Time-series forecasting suggested that overall costs are unlikely to fall below key thresholds within the next decade. The findings indicate that while genomic sequencing is becoming less expensive, the total cost of delivering WGA-guided cancer care remains substantial, underscoring the need for continued evaluation of its economic sustainability.
Automated high throughput nucleic acid purification from formalin-fixed paraffin-embedded tissue samples for next generation sequence analysisThis study developed and optimized automated methods for extracting DNA and RNA from formalin-fixed, paraffin-embedded (FFPE) tissue samples for next-generation sequencing. Although FFPE samples are widely available in pathology archives, their use in genomic studies is limited by nucleic acid damage and challenges with extraction. Researchers established a scalable magnetic bead-based extraction workflow that successfully generated sequencing libraries from low-input FFPE samples with high success rates. This approach enables larger retrospective studies and supports the use of archived clinical specimens for genomic research.
Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast CancerThis observational study evaluated whether homologous recombination deficiency (HRD) mutation signatures can predict response to platinum-based chemotherapy in 93 patients with advanced breast cancer. Using whole genome sequencing of tumors and matched normals, the researchers applied the HRDetect algorithm, which accurately identified BRCA1/2-mutated cases. Importantly, high HRDetect scores were also associated with improved clinical outcomes on platinum therapy, including higher rates of clinical improvement, longer treatment duration, and increased overall survival, even after adjusting for BRCA1/2 status. The findings suggest that HRD mutational signatures may serve as independent predictive biomarkers for platinum sensitivity in breast cancer.
Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancerThis study reports two cases of advanced, treatment-refractory cancers—lung adenocarcinoma and cholangiocarcinoma—identified through whole genome and transcriptome sequencing as harboring NRG1 gene fusions. One patient had an SDC4–NRG1 fusion consistent with previously reported lung cancer cases, while the other carried a novel ATP1B1–NRG1 fusion not previously described in cholangiocarcinoma. Integrative genomic analysis supported targeting the HER-family signaling pathway, and both patients were treated with the pan-HER inhibitor afatinib, resulting in significant and durable clinical responses. At progression, no clear genomic resistance mechanisms were identified. The findings support NRG1 fusions as actionable, tumor-agnostic targets for HER-directed therapy.
Detection and genomic characterization of a mammary-like adenocarcinomaThis case report describes the use of whole genome and transcriptome sequencing to guide diagnosis and treatment in a patient initially diagnosed with vulvar adenocarcinoma. Integrative genomic and transcriptomic analysis, compared against TCGA pan-cancer datasets, suggested that the tumor more closely resembled a primary HER2-positive mammary-like adenocarcinoma rather than a primary vulvar cancer. This reclassification was confirmed by immunohistochemistry. Based on the revised diagnosis, the patient was treated using HER2-directed breast cancer regimens, including chemotherapy and targeted therapy. The study highlights how comprehensive genomic profiling can refine tumor classification and directly influence therapeutic decision-making in diagnostically challenging cancers.
Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinomaThis study reports whole genome and transcriptome sequencing of a pelvic leiomyosarcoma in a woman with a germline CHEK2:c.1100delC variant and a concurrent metastatic invasive ductal breast carcinoma. Despite multiple alterations affecting DNA double-strand break repair pathways, including germline CHEK2 mutation and somatic RAD51B structural variants, the tumor did not display a clear homologous recombination deficiency signature. Instead, genomic analysis revealed a t(12;14) translocation involving RAD51B and regulatory disruption near HMGA2, accompanied by strong overexpression of HMGA2 and PLAG1—features more typically associated with benign leiomyomas. The findings suggest that RAD51B rearrangements and HMGA2 activation may play key roles in leiomyosarcoma development and illustrate the complexity of interpreting DNA repair gene alterations in tumor biology.
Carcinoma ex pleomorphic adenoma: case report and options for systemic therapyThis case report describes a patient with carcinoma ex pleomorphic adenoma (CXPA) of the parotid gland requiring systemic therapy for recurrent, unresectable disease. Treatment decisions were informed by both published evidence for salivary gland malignancies and whole genome and transcriptome sequencing of the tumour. The patient received multiple systemic regimens, with cyclophosphamide, doxorubicin, and cisplatin achieving the best response as a partial remission. In contrast, therapies selected based on genomic findings, including sorafenib and vismodegib, showed limited clinical benefit. The study highlights the biological complexity of malignant transformation in CXPA and suggests that targeting single molecular pathways may be insufficient for durable disease control.
Knowledge, attitudes, and values among physicians working with clinical genomics: a survey of medical oncologistsThis study surveyed medical oncologists in British Columbia participating in the Personalized Onco-Genomics (POG) program to assess genomic literacy and attitudes toward clinical genomics. Among 31 respondents, knowledge of genomic technologies ranged from low to moderate, with oncologists outside major urban centres reporting lower familiarity than those in Vancouver. A substantial proportion felt that medical training does not adequately cover genomics, although most anticipated a major future impact of genomics on drug discovery and treatment selection. Key barriers identified included cost, patient understanding, and uncertainty about clinical utility. The findings highlight the need for improved genomic education to support integration of precision oncology into routine cancer care.
Personalized oncogenomics in the management of gastrointestinal carcinomas-early experiences from a pilot studyThis report describes three cases of metastatic gastrointestinal carcinomas analyzed using whole genome and transcriptome sequencing within the Personalized Onco-Genomics program. In each case, real-time genomic profiling supported diagnostic clarification and treatment selection across different tumour types. One case of cancer of unknown primary was reclassified as cholangiocarcinoma based on an IDH1 mutation and additional molecular features. Another colorectal cancer case with a BRAF V600E mutation informed targeted therapy decisions, while a third appendiceal adenocarcinoma showed widespread pathway activation and oncogene overexpression. Overall, the study demonstrates that integrated genomic profiling can rapidly generate clinically actionable insights to guide diagnosis and therapy in complex gastrointestinal cancers.
Clinicians identify high need to increase their genomic literacy to applied cancer genomicsThis survey study assessed genomic literacy and attitudes among medical oncologists participating in the Personalized Onco-Genomics (POG) program in British Columbia. Among 31 respondents, nearly half reported limited knowledge of newer genomic technologies, with lower familiarity reported by clinicians outside the main urban centre. Many respondents felt that medical training does not adequately cover genomics, though most anticipated that genomic technologies would significantly influence drug discovery and treatment selection within five years. Key concerns included cost, patient understanding, and uncertain clinical utility of genomic data. Overall, the findings highlight gaps in genomic education and the need for ongoing training as precision oncology becomes more integrated into clinical practice.
Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung CancerThis study compared different methods of assessing PD-L1 expression as a biomarker for response to PD-1 checkpoint inhibitors in non-small cell lung cancer (NSCLC). Using tissue microarrays from matched primary and metastatic tumors, the researchers evaluated multiple immunohistochemistry (IHC) approaches and RNA in situ hybridization (RNA ISH), with additional integration of whole genome and transcriptome data. While the IHC methods showed moderate agreement overall, concordance improved when results were calibrated against RNA expression. Notably, PD-L1 status was discordant between primary and metastatic sites in a significant proportion of cases. The findings suggest that RNA-based approaches may complement IHC and improve consistency in biomarker assessment for immunotherapy selection.
ETV6-NTRK3 Is Expressed in a Subset of ALK-Negative Inflammatory Myofibroblastic TumorsThis study reports the molecular characterization of an inflammatory myofibroblastic tumor (IMT), focusing on ALK-negative cases where driver alterations are less well defined. Whole genome and transcriptome sequencing of an aggressive lung IMT in a 17-year-old patient identified an ETV6–NTRK3 fusion, which was confirmed by additional molecular assays. The researchers then screened a cohort of ALK-negative IMTs and found evidence of ETV6 rearrangements in additional cases, with one also confirmed to carry the same fusion transcript. The findings expand the known spectrum of IMTs driven by oncogenic tyrosine kinase fusions and reinforce the clinical relevance of comprehensive genomic profiling for identifying actionable targets in rare tumors.
Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancerThis case report describes a patient with treatment-refractory, mismatch repair-deficient metastatic colorectal cancer who underwent whole genome and transcriptome sequencing as part of a personalized oncogenomics program. Integrative genomic analysis identified overexpression of the AP-1 transcriptional complex, which suggested a potential therapeutic vulnerability involving the renin–angiotensin system. Based on this finding, the angiotensin II receptor blocker irbesartan was repurposed as a treatment option. The patient subsequently experienced a dramatic and durable clinical response. The study illustrates how comprehensive genomic profiling and bioinformatic interpretation can generate novel, non-traditional therapeutic hypotheses that may lead to effective personalized treatment strategies.
Molecular etiology of an indolent lymphoproliferative disorder determined by whole-genome sequencingThis case report describes the use of whole genome and transcriptome sequencing to evaluate a patient with an unclassifiable small lymphoproliferative disorder. Integrated genomic analysis was used to compare variant and expression patterns against known lymphoma profiles to help refine diagnosis and identify potential therapeutic directions. The mutational profile most closely resembled diffuse large B-cell lymphoma, while gene expression patterns were more consistent with chronic lymphocytic leukemia. A key finding was a predicted truncating mutation in NOTCH2, a gene previously implicated in lymphomagenesis. Overall, the study demonstrates how multi-layered genomic profiling can aid in resolving ambiguous hematologic diagnoses and inform potential treatment strategies.
Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancersThis study describes the early implementation of whole genome analysis within the Personalized Onco-Genomics (POG) program for patients with advanced, incurable cancers. Between 2012 and 2014, 100 patients underwent tumor and blood sequencing, with integrative analysis of genomic and transcriptomic data used to identify potential driver alterations and therapeutic targets. Of the 78 patients with successful sequencing, 55 had findings considered clinically actionable, and 23 ultimately received treatments guided by genomic results. The study highlights the feasibility of integrating genome-scale sequencing into routine multidisciplinary oncology care and demonstrates how such data can directly influence treatment decisions in a subset of patients with advanced disease.
Integrative genomic analysis of ghost cell odontogenic carcinomaThis integrative genomic and transcriptomic study describes the first molecular characterization of a GCOC, a rare tumour with previously unclassified biological features. Gene expression profiling showed no clear similarity to any TCGA tumour type, including other head and neck squamous cell carcinoma sub-sites, suggesting that GCOC may represent a distinct molecular entity rather than one defined by anatomical origin. Genomic analysis revealed key driver alterations including homozygous deletion of RB1, along with changes in PTEN and RASSF4, supporting disruption of major tumour suppressor pathways. Additional novel findings included an APC frameshift mutation, a UBR5 splice-site mutation, activation of SHH signalling components, and a TCF4–PTPRG fusion potentially affecting tumour suppression and epithelial–mesenchymal transition. Overall, the study highlights extensive molecular heterogeneity and suggests unique oncogenic mechanisms in GCOC, warranting further investigation.
Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencingThis study presents whole genome and transcriptome sequencing of two patients with peritoneal mesothelioma, a rare and aggressive malignancy. Integrative genomic analysis identified mutations in known mesothelioma-associated genes, including NF2, CDKN2A, and LATS2, along with evidence of MET pathway activation in both cases. One tumour exhibited a hypermutated phenotype with a markedly elevated number of single nucleotide variants and was associated with a more favourable clinical outcome despite high-risk histology. The study provides the first reported whole genome characterization of peritoneal mesothelioma and demonstrates how genomic profiling can reveal biologically and potentially clinically relevant insights to guide understanding and management of this disease.
Diagnostic value of next-generation sequencing in an unusual sphenoid tumorThis study evaluates the clinical utility of rapid whole genome and transcriptome sequencing within the Personalized Onco-Genomics initiative. The authors demonstrate that sequencing, analysis, and reporting could be completed within approximately five weeks, making clinical application feasible. A key case involved a patient initially diagnosed with undifferentiated squamous cell carcinoma, whose tumour was reclassified as an SMARCB1-deficient rhabdoid tumour after detection of a homozygous SMARCB1 deletion. This revised diagnosis led to a change in chemotherapy and a complete nodal response. The study highlights how comprehensive genomic profiling can improve diagnostic accuracy and directly influence treatment decisions in complex cancer cases.
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitorsThis study uses massively parallel whole genome and transcriptome sequencing to characterize a rare adenocarcinoma of the tongue before and after treatment. Genomic analysis of the pretreatment tumour revealed extensive copy number gains and overexpression of multiple genes, with evidence suggesting RET as a key oncogenic driver. Based on these findings, the patient was treated with RET-targeted therapies including sunitinib and sorafenib, resulting in temporary disease stabilization before progression. Sequencing of recurrent disease showed additional genomic alterations consistent with activation of MAPK and AKT signalling pathways, indicating acquired resistance. The study demonstrates how comprehensive genomic profiling can guide treatment selection and reveal tumour evolution under therapeutic pressure.